Key Takeaways
- Federal Minister for Finance and Revenue, Senator Muhammad Aurangzeb, highlighted the need for transparent and evidence-based drug pricing.
- The meeting discussed recommendations from the Drug Pricing Committee and the Policy Board of DRAP regarding new drug price fixation cases.
- DRAP’s first drug testing laboratory has secured prequalification from WHO, enhancing Pakistan's pharmaceutical quality framework.
Federal Minister for Finance and Revenue, Senator Muhammad Aurangzeb, chaired a significant meeting on Friday to discuss the recommendations of the Drug Pricing Committee and the Policy Board of the Drug Regulatory Authority of Pakistan (DRAP). The primary focus was on ensuring transparent and evidence-based drug pricing decisions.
During the 8th meeting of the cabinet committee constituted by the Prime Minister, Aurangzeb emphasized the importance of balancing patient access to essential medicines with the sustainability of pharmaceutical supply and affordability for patients. He stressed that all decisions should be consultative and guided by broader public interest.
The meeting received a detailed presentation from DRAP on various aspects including new drug price fixation cases, hardship applications, pricing matters, and the availability of essential medicines. The Finance Division provided an update on progress made since the previous meeting and outlined proposals for consideration.
Aurangzeb highlighted the need for clear public engagement to explain the rationale behind decisions affecting critical medicines. He underscored that transparency is crucial in maintaining trust among stakeholders and ensuring fair pricing practices.
DRAP, a key regulatory body responsible for approving new medicines, plays a vital role in ensuring the quality of pharmaceuticals in Pakistan. The committee’s efforts are aligned with international standards to enhance the global credibility of Pakistan's pharmaceutical sector.
In a significant development, DRAP’s first drug testing laboratory secured prequalification from the World Health Organization (WHO) in April 2026. This move is expected to significantly boost the global credibility of Pakistan’s pharmaceutical quality framework and facilitate exports.
